Publication Abstract from PubMed
A little is more than enough: Aldose reductase (AR) is a potential target in a wide range of diseases but its utility may be limited by the side effects caused by complete inhibition. Furthermore, known inhibitors of AR have suffered in clinical evaluation due to poor bioavailability. Here, the clinically used antiprotozoal drug nitazoxanide with proven bioavailability has been shown to partially inhibit AR, potentially circumventing the negatives effects of complete enzyme inhibition.
Partial Inhibition of Aldose Reductase by Nitazoxanide and Its Molecular Basis.,Zheng X, Zhang L, Chen W, Chen Y, Xie W, Hu X ChemMedChem. 2012 Aug 13. doi: 10.1002/cmdc.201200333. PMID:22890894[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
